The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission: Cushing’s syndrome and metabolic/cardiovascular outcomes
Abstract
OBJECTIVE: Cushing's syndrome is associated with several comorbidities responsible for the increased cardiovascular risk, not only during the active phase but also after disease remission. DESIGN: In 29 patients with Cushing's syndrome (14 Cushing's diseases and 15 adrenal adenomas), waist circumference, fasting and 2-h glucose after oral glucose tolerance test (OGTT), lipid profile and blood pressure were evaluated during the active disease and 1 year after remission and compared with those in 29 sex-, age- and BMI-matched controls. RESULTS: During the active disease, waist circumference, 2-h glucose after OGTT, total and LDL cholesterol were higher in patients with Cushing's syndrome than in controls (P < 0·001) but similar in Cushing's disease and adrenal adenomas. The prevalence of impaired glucose tolerance (IGT), diabetes mellitus, dyslipidaemia and hypertension was higher (P < 0·001) in patients with Cushing's syndrome (27%, 24%, 59% and 72%) than in controls (10%, 0%, 21% and 10%), with no significant difference between Cushing's disease and adrenal adenomas. One year following hormonal remission, waist circumference persisted higher than in controls (P < 0·05) in both Cushing's disease and adrenal adenomas. Metabolic and cardiovascular abnormalities were still present in both groups, although with a lower prevalence, as well as with a more marked decrease in adrenal adenomas (P < 0·05 vs active disease for IGT, dyslipidaemia and hypertension). CONCLUSIONS: These results show that chronic hypercortisolism, independently of its aetiology, contributes to metabolic impairment and increased cardiovascular risk, while these abnormalities mostly persist in patients with previous Cushing's disease after hormonal remission. Pituitary hormonal deficiencies, hormonal replacement treatments and/or incomplete cure from Cushing's disease may account for these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“From % to % of patients with endogenous CS have DM, and % to % have defective glucose tolerance, so the overall prevalence of glucose metabolism impairments can come close to %, as shown in Table (, , -).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [186]
In the citing paper
“Diabetes can develop irrespective of the etiology of cortisol excess in patients with endogenous CS (, ), and its onset does not seem to correlate with the duration of the latter disease ().”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [186]
In the citing paper
“Controlling hypercortisolism is the first step toward improving glucose metabolism in patients with endogenous CS, but different treatments for hypercortisolism may affect the outcome of diabetes, regardless of how well cortisol excess is corrected (, , , , , , ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [186]
In the citing paper
“Other prospective studies [Faggiano et al., (); Giordano et al., ()] reported similar findings in patients with CS before and year after remission was achieved thanks to pituitary neurosurgery, pituitary irradiation, or adrenalectomy.”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [186]
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
World Health Organization, I. S. O. H. W. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,667
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Newell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,258
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Glucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.117 · Cited by 505
Colao, A., Pivonello, R., Spiezia, S., Faggiano, A., Ferone, D., Filippella, M., Marzullo, P., Cerbone, G., Siciliani, M., & Lombardi, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5896 · Cited by 450
Faggiano, A., Pivonello, R., Spiezia, S., De Martino, M. C., Filippella, M., Di Somma, C., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021558 · Cited by 358
Adrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278
Glucocorticoids and insulin resistance: old hormones, new targets
Andrews, R. C., & Walker, B. R. (1999) · Clinical Science · doi:10.1042/cs19980388 · Cited by 266
Blood-pressure reduction and cardiovascular risk in HOPE study
Sleight, P., Yusuf, S., Pogue, J. M., Tsuyuki, R. T., Díaz, R., & Probstfield, J. L. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07186-0 · Cited by 219
Pathophysiology of Dyslipidemia in Cushing’s Syndrome
Arnaldi, G., Scandali, V. M., Trementino, L., Cardinaletti, M., Appolloni, G., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314213 · Cited by 194
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Barahona, M. J., Sucunza, N., Resmini, E., Fernández‐Real, J. M., Ricart, W., Moreno‐Navarrete, J. M., Puig, T., Farrerons, J., & Webb, S. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0766 · Cited by 161
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
Webb, S. M., Mo, D., Lamberts, S. W. J., Melmed, S. K., Cavagnini, F., Giraldi, F. P., Strasburger, C. J., Zimmermann, A. G., Woodmansee, W. W., & on behalf of the International HypoCCS Advisory Board (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0806 · Cited by 63
Loss of Body Cell Mass in Cushing's Syndrome: Effect of Treatment
Pirlich, M., Biering, H., Gerl, H., Ventz, M., Schmidt, B., Ertl, S., & Lochs, H. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8321 · Cited by 49
Ueland, T., Kristo, C., Godang, K., Aukrust, P., & Bollerslev, J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021030 · Cited by 34
Resmini, E., Farkas, C., Murillo, B. D., Barahona, M. J., Vives, A. S., Martínez-Momblán, M.-A., Roig, O., Ybarra, J., Geli, C., & Webb, S. M. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1255032 · Cited by 24
A User's Guide to the Evaluation of Statistical Packages and Systems
Nelder, J. A. (1974) · International Statistical Review · doi:10.2307/1402986 · Cited by 10
Cited by
Sorted by citations
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., Martino, M. C. D., Newell-Price, J. D. C., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 694
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Obesity and dementia: Adipokines interact with the brain
Arnoldussen, I. A. C., Kiliaan, A. J., & Gustafson, D. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.002 · Cited by 226
Metadata
- Authors
- Giordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., & Arvat, E.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Arvat, Emanuela
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2011-08-05
- Volume
- 75
- Issue
- 3
- Pages
- 354-360
- ISSN
- 0300-0664 (ISSN-L)
- OpenAlex
- W1945278090
- Cited by
- 122
- References
- 28
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 10 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 7 · 2018: 10 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 10 · 2013: 8 · 2012: 6
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Università degli Studi di Torino
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, Cushing's disease, adrenal adenoma, hypercortisolism, cardiovascular risk, metabolic comorbidities, impaired glucose tolerance, diabetes mellitus, dyslipidemia, hypertension, waist circumference, remission, hormone replacement therapy, hypopituitarism
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Fasting, Female, Humans, Hydrocortisone, Hypertension, Lipids, Male, Middle Aged, Remission Induction, Risk Factors, Time Factors, Multivariate Analysis, Linear Models, Adrenocortical Adenoma, Metabolic Syndrome, Pituitary ACTH Hypersecretion, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review